

PRESS RELEASE

Hansa Biopharma announces planned departure of Chief Scientific Officer Christian Kjellman

Christian Kjellman also served as Chief Operating Officer since January 2020

Lund, Sweden, 30 January 2023. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Christian Kjellman, Chief Scientific Officer and Chief Operating Officer, has decided to leave the company in 2024. Effective immediately, Commercial Operations will report directly to President and CEO Søren Tulstrup and a search is underway for a new Chief Scientific Officer (CSO).

Søren Tulstrup, President and CEO, Hansa Biopharma said, “Christian has been an important part of Hansa Biopharma since 2008 helping advance the Company’s research and development projects through several critical milestones including regulatory approval of our first drug candidate. Additionally, in 2020 Christian assumed a dual leadership role ensuring tight integration and connectivity between the R&D and Commercial Operations functions during the early launch phase of the Company’s first commercial product. We are grateful to Christian for his passionate commitment and many contributions to the Company.”

“In light of the approval and successful early launch of our most advanced molecule, imlifidase, in its first indication and with the lead candidate from our next generation NiceR program ready to enter the clinic, I feel now is the right time to initiate a planned transition to new leadership. It has been an immense honor to work hand in hand with the many talented colleagues at Hansa Biopharma and together advance much needed science for people with serious and life-threatening rare diseases”, said Christian Kjellman. “I have no doubt that Hansa will continue to deliver innovative science and medicines.”

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.

--- ENDS ---

Contacts for more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709 298 269

E: klaus.sindahl@hansabiopharma.com

Stephanie Kenney, *VP Global Corporate Affairs*

M: +1 (484) 319 2802

E: stephanie.kenney@hansabiopharma.com